Arabic Arabic English English French French German German
dark

PDS Biotech Announces Agreement with University of Georgia to License Novel Proteins for Versamune-based Universal Flu Vaccine

PDS Biotechnology Corporation today announced an agreement to license COBRA (Computationally Optimized Broadly Reactive Antigen) antigens from the University of Georgia initially for use in the clinical development of its infectious disease immunotherapy pipeline, PDS0202, a universal flu vaccine candidate. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Cures for the health insurance enrollment blues

Next Post

Masimo Launches Dual SET® Pulse Oximetry

Related Posts
Total
0
Share